CBMG aims for large-scale CAR-T capacity

January 26, 2017 Christoph Graener

Cellular Biomedicine Group (CBMG) CEO Bizuo (Tony) Liu differentiates plans for chimeric antigen receptor-T cell development in part by large-scale production in the company’s home country, China. In an announcement on Jan. 3, the Shanghai-based immunotherapy and stem cell therapy company said it was expanding cell production in China to enable production of personalized CAR-T treatments in China for 10,000 patients annually. The company is focusing on becoming a leader in the area in China, but is manufacturing therapies according to both Chinese and US standards, Liu said in an interview at Biotech Showcase.

Interviewer: Emily Hayes – Senior Writer, Scrip and The Pink Sheet
Interviewee: Tony Liu – CEO, CBMG

Previous Article
Second Genome CEO predicts paradigm shift with microbiome discovery

California biotech, which has backing from major pharmas, explains the application of its microbiome discov...

Next Article
MEI Pharma rides wave of interest in AML

MEI Pharma CEO Dan Gold explains Phase III plans for the oral HDAC inhibitor pracinostat in AML and why the...